Revolution Medicines, Inc.
RVMD
$39.12
$0.090.23%
| Weiss Ratings | RVMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | RVMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Very Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Fair | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | RVMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.35 | |||
| Price History | RVMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -0.26% | |||
| 30-Day Total Return | -8.92% | |||
| 60-Day Total Return | -12.50% | |||
| 90-Day Total Return | -28.99% | |||
| Year to Date Total Return | -11.09% | |||
| 1-Year Total Return | 22.90% | |||
| 2-Year Total Return | 70.23% | |||
| 3-Year Total Return | 113.77% | |||
| 5-Year Total Return | 95.60% | |||
| 52-Week High % Change | -37.31% | |||
| 52-Week Low % Change | 32.39% | |||
| Price | RVMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $62.40 | |||
| 52-Week Low Price | $29.55 | |||
| 52-Week Low Price (Date) | Apr 05, 2024 | |||
| 52-Week High Price (Date) | Nov 11, 2024 | |||
| Valuation | RVMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 7.27B | |||
| Enterprise Value | 5.12B | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -3.57 | |||
| Earnings Per Share Growth | -5.49% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 3.21 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $39.12 | |||
| Enterprise Value/EBITDA (TTM) | -7.50 | |||
| Enterprise Value/EBIT | -7.42 | |||
| Market Cap Category | Mid Cap | |||
| Dividends and Shares | RVMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 173.76M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | RVMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 650 481 6801 | |||
| Address | 700 Saginaw Drive Redwood City, CA 94063 | |||
| Website | www.revmed.com | |||
| Country | United States | |||
| Year Founded | 2014 | |||
| Profitability | RVMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | RVMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -18.66% | |||
| Return on Equity | -- | |||
| Income Statement | RVMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -470.64M | |||
| EBITDA (TTM) | -683.00M | |||
| EBIT (TTM) | -689.52M | |||
| Net Income (TTM) | -600.09M | |||
| Net Income Avl. to Common (TTM) | -600.09M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -20.45% | |||
| EPS Diluted (TTM) | -3.57 | |||
| EPS Diluted Growth (Q YOY) | 2.13% | |||
| Balance Sheet | RVMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 2.29B | |||
| Cash Per Share (Q) | $13.18 | |||
| Total Current Assets (Q) | 2.33B | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 2.27B | |||
| Current Ratio (Q) | 14.200 | |||
| Book Value Per Share (Q) | $12.19 | |||
| Total Assets (Q) | 2.56B | |||
| Total Current Liabilities (Q) | 163.91M | |||
| Total Debt (Q) | 135.84M | |||
| Total Liabilities (Q) | 293.10M | |||
| Total Common Equity (Q) | 2.27B | |||
| Cash Flow | RVMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -554.39M | |||
| Cash from Financing (TTM) | 959.41M | |||
| Net Change in Cash (TTM) | -152.42M | |||
| Levered Free Cash Flow (TTM) | -347.69M | |||
| Cash from Operations (TTM) | -557.44M | |||
